An Analysis of the Biological Disease-modifying Antirheumatic Drug-free Condition of Adalimumab-treated Rheumatoid Arthritis Patients-Reference-Cited by-同舟云学术

An Analysis of the Biological Disease-modifying Antirheumatic Drug-free Condition of Adalimumab-treated Rheumatoid Arthritis Patients

Published:2019-02-15 Issue:4 Volume:58 Page:511-519
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Ito Satoshi¹,Kobayashi Daisuke¹²,Hasegawa Eriko¹²,Takai Chinatsu¹²,Nemoto Tetsuya¹,Lee Hyunho¹,Abe Asami¹,Otani Hiroshi¹,Ishikawa Hajime¹,Murasawa Akira¹,Narita Ichiei²,Nakazono Kiyoshi¹

Affiliation:

1. Department of Rheumatology, Niigata Rheumatic Center, Japan

2. Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/58/4/58_1332-18/_pdf

Reference24 articles.

1. 1. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54: 26-37, 2006.

2. 2. Smolen JS, van der Heijde DM, Keystone EC, et al. Association of joint space narrowing with impairment of physical function and work ability in patients with early rheumatoid arthritis: protection beyond disease control by adalimumab plus methotrexate. Ann Rheum Dis 72: 1156-1162, 2013.

3. 3. Burmester GR, Kivitz AJ, Kupper H, et al. Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial. Ann Rheum Dis 74: 1037-1044, 2015.

4. 4. Oh K, Ito S, Unno M, et al. Decrease in disease activity of rheumatoid arthritis during treatment with adalimumab depends on the dose of methotrexate. Intern Med 54: 1035-1041, 2015.

5. 5. Detert J, Bastian H, Listing J, et al. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study. Ann Rheum Dis 72: 844-850, 2013.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prevalence and predictors of sustained remission/low disease activity after discontinuation of induction or maintenance treatment with tumor necrosis factor inhibitors in rheumatoid arthritis: a systematic and scoping review;Arthritis Research & Therapy;2023-11-20

2. The long-term observation of patients with rheumatoid arthritis who achieved a biological disease-modifying antirheumatic drug-free condition with adalimumab;Modern Rheumatology;2020-10-12

3. Two-year Outcomes of Infliximab Discontinuation in Patients with Rheumatoid Arthritis: A Retrospective Analysis from a Single Center;Internal Medicine;2020-08-15

4. AB0297 THE LONG-TERM OBSERVATION OF PATIENTS WITH RHEUMATOID ARTHRITIS WHO ACHIEVED A BIO-FREE CONDITION WITH ADALIMUMAB.;Annals of the Rheumatic Diseases;2020-06